Cargando…

Prognostic Value of (18)F-Choline PET/CT in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Radium-223

We aimed to investigate the role of positron emission computed tomography (PET/CT) with (18)F-choline for predicting the outcome of metastatic castration-resistant prostate cancer (mCRPC) submitted to treatment with Radium-223 ((223)Ra-therapy). Clinical records of 20 mCRPC patients submitted to PET...

Descripción completa

Detalles Bibliográficos
Autores principales:	Filippi, Luca, Spinelli, Gian Paolo, Chiaravalloti, Agostino, Schillaci, Orazio, Equitani, Francesco, Bagni, Oreste
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7760591/ https://www.ncbi.nlm.nih.gov/pubmed/33266047 http://dx.doi.org/10.3390/biomedicines8120555

Ejemplares similares

PET/CT with (18)F-choline or (18)F-FDG in Hepatocellular Carcinoma Submitted to (90)Y-TARE: A Real-World Study
por: Filippi, Luca, et al.
Publicado: (2022)

Detection Rate and Clinical Impact of PET/CT with (18)F-FACBC in Patients with Biochemical Recurrence of Prostate Cancer: A Retrospective Bicentric Study
por: Filippi, Luca, et al.
Publicado: (2022)

Cerebellar Metastases from Prostate Cancer Detected by PET/CT with (18)F-Choline
por: Filippi, Luca, et al.
Publicado: (2022)

Radium-223 in metastatic castration resistant prostate cancer
por: Vuong, Winston, et al.
Publicado: (2014)

Prognostic and Theranostic Applications of Positron Emission Tomography for a Personalized Approach to Metastatic Castration-Resistant Prostate Cancer
por: Filippi, Luca, et al.
Publicado: (2021)

Radium-223-Dichloride in Castration Resistant Metastatic Prostate Cancer—Preliminary Results of the Response Evaluation Using F-18-Fluoride PET/CT
por: Kairemo, Kalevi, et al.
Publicado: (2015)

18F-FDOPA PET/CT SUV-Derived Indices and Volumetric Parameters Correlation in Patients with Primary Brain Tumors
por: Chiaravalloti, Agostino, et al.
Publicado: (2021)

Radium-223 for the treatment of castration-resistant prostate cancer
por: El-Amm, Joelle, et al.
Publicado: (2015)

Is interim (18)F-fluoride PET/CT a predictor of outcomes after radium-223 therapy?
por: Etchebehere, Elba, et al.
Publicado: (2019)

Mycobacterial Lymphadenitis in a Human Immunodeficiency Virus-Infected Patient: Usefulness of 18F-Fluorodeoxyglucose Positron Emission Tomography for Diagnosis and Monitoring the Response to Treatment
por: Filippi, Luca, et al.
Publicado: (2019)

Radium-223 and metastatic castration-resistant prostate cancer: All that glitters is not gold
por: Aprile, Carlo, et al.
Publicado: (2016)

Dutch Economic Value of Radium-223 in Metastatic Castration-Resistant Prostate Cancer
por: Peters, Michel L., et al.
Publicado: (2017)

Practical recommendations for radium-223 treatment of metastatic castration-resistant prostate cancer
por: Du, Yong, et al.
Publicado: (2017)

Radium-223 for the Management of Bone Metastases in Castration-Resistant Prostate Cancer
por: Cox, Heather, et al.
Publicado: (2015)

Correction to: Dutch Economic Value of Radium-223 in Metastatic Castration-Resistant Prostate Cancer
por: Peters, Michel L., et al.
Publicado: (2018)

Pharmacodynamic study of radium-223 in men with bone metastatic castration resistant prostate cancer
por: Armstrong, Andrew J., et al.
Publicado: (2019)

Overall survival prediction in metastatic castration-resistant prostate cancer treated with radium-223
por: Vidal, Monica, et al.
Publicado: (2020)

A Rare Case of Primary Uterine Non-Hodgkins's Lymphoma with Involvement of Right Ovary: Staging with 18F FDG PET/CT and Iodinated Contrast CT
por: Lamacchia, Feliciana, et al.
Publicado: (2019)

Multimodality radionuclide imaging in fever of unknown origin presenting with a solitary spleen lesion
por: Filippi, Luca, et al.
Publicado: (2022)

Fluorine-18-fluorocholine PET/CT parameters predictive for hematological toxicity to radium-223 therapy in castrate-resistant prostate cancer patients with bone metastases: a pilot study
por: Vija Racaru, Lavinia, et al.
Publicado: (2018)

Usefulness of PET/CT with (18)F-FDG in Patients with Differentiated Thyroid Carcinoma after Radioiodine Therapy: An Italian Multicenter Study
por: Filippi, Luca, et al.
Publicado: (2021)

(18)F-Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography Imaging of Inferior Vena Cava Tumor Thrombus Extending into the Right Atrium in a Patient with Cholangiocarcinoma Treated with (90)Y-Microspheres
por: Filippi, Luca, et al.
Publicado: (2018)

Somatostatin Receptor Targeted PET-Imaging for Diagnosis, Radiotherapy Planning and Theranostics of Meningiomas: A Systematic Review of the Literature
por: Filippi, Luca, et al.
Publicado: (2022)

Treatment of castration-resistant prostate cancer and bone metastases with radium-223 dichloride
por: Lien, Lise Marie E, et al.
Publicado: (2015)

Positron Emission Tomography (PET) and Neuroimaging in the Personalized Approach to Neurodegenerative Causes of Dementia
por: Ricci, Maria, et al.
Publicado: (2020)

Radium-223 Chloride: A New Treatment Option for Metastatic Castration-Resistant Prostate Carcinoma
por: Pinto, Álvaro, et al.
Publicado: (2012)

Evolving treatment approaches for the management of metastatic castration-resistant prostate cancer – role of radium-223
por: Mukherji, Deborah, et al.
Publicado: (2014)

Radium-223 in patients with metastatic castration-resistant prostate cancer: Efficacy and safety in clinical practice
por: Prelaj, Arsela, et al.
Publicado: (2019)

(18)F–Choline PET/CT Identifies High-Grade Prostate Cancer Lesions Expressing Bone Biomarkers
por: Urbano, Nicoletta, et al.
Publicado: (2019)

Utility of F-18 FDG PET/CT for Detection of Bone Marrow Metastases in Prostate Cancer Patients Treated with Radium-223
por: Maruyama, Kaoru, et al.
Publicado: (2018)

Role of Baseline and Post-Therapy 18F-FDG PET in the Prognostic Stratification of Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Treated with Radium-223
por: Bauckneht, Matteo, et al.
Publicado: (2019)

Radium-223 Therapy for Patients with Metastatic Castrate-Resistant Prostate Cancer: An Update on Literature with Case Presentation
por: Nguyen, Nghi C., et al.
Publicado: (2016)

Pain predicts overall survival in men with metastatic castration-resistant prostate cancer treated with radium-223
por: Roviello, Giandomenico, et al.
Publicado: (2018)

Editorial Comment: Overall survival prediction in metastatic castration-resistant prostate cancer treated with radium-223
por: dos Reis, Rodolfo Borges, et al.
Publicado: (2020)

Radium-223 Treatment of Patients with Metastatic Castration Resistant Prostate Cancer: Biomarkers for Stratification and Response Evaluation
por: van der Zande, Kim, et al.
Publicado: (2021)

Impact of timing of radium‑223 administration on the survival of patients with bone metastatic castration‑resistant prostate cancer
por: Makita, Kenji, et al.
Publicado: (2023)

Functional correlates of TSH, fT3 and fT4 in Alzheimer disease: a F-18 FDG PET/CT study
por: Chiaravalloti, Agostino, et al.
Publicado: (2017)

Interim and end-treatment (18)F-Fluorocholine PET/CT and bone scan in prostate cancer patients treated with Radium 223 dichloride
por: García Vicente, Ana María, et al.
Publicado: (2021)

uPAR PET/CT for Prognostication and Response Assessment in Patients with Metastatic Castration-Resistant Prostate Cancer Undergoing Radium-223 Therapy: A Prospective Phase II Study
por: Fosbøl, Marie Øbro, et al.
Publicado: (2021)

Initial Staging of Hodgkin’s Disease: Role of Contrast-Enhanced (18)F FDG PET/CT
por: Chiaravalloti, Agostino, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_ag5filpr3k8kdjgjc9t2gv2qlm